405 related articles for article (PubMed ID: 30305612)
1. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
4. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
[TBL] [Abstract][Full Text] [Related]
6. Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.
Huang C; Tian Y; Peng R; Zhang C; Wang D; Han S; Jiao C; Wang X; Zhang H; Wang Y; Li X
J Gastroenterol Hepatol; 2015 Feb; 30(2):421-33. PubMed ID: 25168293
[TBL] [Abstract][Full Text] [Related]
7. Calcium-sensing receptor promotes tumor proliferation and migration in human intrahepatic cholangiocarcinoma by targeting ERK signaling pathway.
Fang Y; Liu L; Liu S; Hu L; Cai W; Wan X; Liu D; He Y; Zhu Z
Eur J Pharmacol; 2020 Apr; 872():172915. PubMed ID: 31926993
[TBL] [Abstract][Full Text] [Related]
8. Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
Andrici J; Goeppert B; Sioson L; Clarkson A; Renner M; Stenzinger A; Tayao M; Watson N; Farzin M; Toon CW; Smith RC; Mittal A; Samra JS; Hugh TJ; Chou A; Lawlor RT; Weichert W; Schirmacher P; Sperandio N; Ruzzenente A; Scarpa A; Gill AJ
Medicine (Baltimore); 2016 Jan; 95(2):e2491. PubMed ID: 26765459
[TBL] [Abstract][Full Text] [Related]
9. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
10. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.
Sakamoto K; Imai K; Higashi T; Taki K; Nakagawa S; Okabe H; Nitta H; Hayashi H; Chikamoto A; Ishiko T; Beppu T; Baba H
Cancer Sci; 2015 Sep; 106(9):1153-62. PubMed ID: 26132727
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
[TBL] [Abstract][Full Text] [Related]
12. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.
Xie N; Cai JB; Zhang L; Zhang PF; Shen YH; Yang X; Lu JC; Gao DM; Kang Q; Liu LX; Zhang C; Huang XY; Zou H; Zhang XY; Song ZJ; Sun HX; Fu BM; Ke AW; Shi GM
Cell Death Dis; 2017 Dec; 8(12):3205. PubMed ID: 29235470
[TBL] [Abstract][Full Text] [Related]
15. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
[TBL] [Abstract][Full Text] [Related]
16. Identification of Homer1 as a potential prognostic marker for intrahepatic cholangiocarcinoma.
Wu SY; Yu MX; Li XG; Xu SF; Shen J; Sun Z; Zhou X; Chen XZ; Tu JC
Asian Pac J Cancer Prev; 2014; 15(7):3299-304. PubMed ID: 24815486
[TBL] [Abstract][Full Text] [Related]
17. High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Huang Y; Kong Y; Zhang L; He T; Zhou X; Yan Y; Zhang L; Zhou D; Lu S; Zhou J; Zhou L; Xie H; Zheng S; Wang W
Biomed Res Int; 2018; 2018():2352139. PubMed ID: 29511671
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro.
Gu S; Chen J; Zhou Q; Yan M; He J; Han X; Qiu Y
Dig Dis Sci; 2020 Feb; 65(2):500-508. PubMed ID: 31489563
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis.
Huang Q; Liu L; Liu CH; You H; Shao F; Xie F; Lin XS; Hu SY; Zhang CH
Asian Pac J Cancer Prev; 2013; 14(2):829-34. PubMed ID: 23621247
[TBL] [Abstract][Full Text] [Related]
20. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Brandi G; Deserti M; Palloni A; Turchetti D; Zuntini R; Pedica F; Frega G; De Lorenzo S; Abbati F; Rizzo A; Di Marco M; Massari F; Tavolari S
Cancer Genet; 2020 Oct; 248-249():57-62. PubMed ID: 33093002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
